The estimated Net Worth of David Madden is at least 4.3 百万$ dollars as of 24 September 2013. David Madden owns over 112,511 units of Dicerna Pharmaceuticals Inc stock worth over 4,300,170$ and over the last 11 years David sold DRNA stock worth over 0$.
David has made over 1 trades of the Dicerna Pharmaceuticals Inc stock since 2013, according to the Form 4 filled with the SEC. Most recently David exercised 112,511 units of DRNA stock worth 384,788$ on 24 September 2013.
The largest trade David's ever made was exercising 112,511 units of Dicerna Pharmaceuticals Inc stock on 24 September 2013 worth over 384,788$. On average, David trades about 14,064 units every 0 days since 2013. As of 24 September 2013 David still owns at least 112,511 units of Dicerna Pharmaceuticals Inc stock.
You can see the complete history of David Madden stock trades at the bottom of the page.
David's mailing address filed with the SEC is 87 Cambridgepark Dr, Cambridge, MA 02140, USA.
Over the last 11 years, insiders at Dicerna Pharmaceuticals Inc have traded over 233,644,011$ worth of Dicerna Pharmaceuticals Inc stock and bought 2,456,100 units worth 36,501,331$ . The most active insiders traders include Capital Management, Llc Kol...、Nicole Vitullo、Peter Kolchinsky. On average, Dicerna Pharmaceuticals Inc executives and independent directors trade stock every 21 days with the average trade being worth of 4,025,674$. The most recent stock trade was executed by Douglas W. Pagan on 15 December 2021, trading 2,050 units of DRNA stock currently worth 78,351$.
Dicerna Pharmaceuticals, Inc. is a biopharmaceutical company focused on discovering, developing and commercializing medicines that are designed to leverage ribonucleic acid interference (RNAi) to silence selectively genes that cause or contribute to disease. Using its proprietary GalXC™ and GalXC-Plus™ RNAi technologies, Dicerna is committed to developing RNAi-based therapies with the potential to treat both rare and more prevalent diseases. By silencing disease-causing genes, Dicerna's GalXC platform has the potential to address conditions that are difficult to treat with other modalities. Initially focused on disease-causing genes in the liver, Dicerna has continued to innovate and is exploring new applications of its RNAi technology with GalXC-Plus, which expands on the functionality and application of its flagship liver-based GalXC technology, and has the potential to treat diseases across multiple therapeutic areas. In addition to its own pipeline of core discovery and clinical candidates, Dicerna has established collaborative relationships with some of the world's leading pharmaceutical companies, including Novo Nordisk A/S, Roche, Eli Lilly and Company, Alexion Pharmaceuticals, Inc., Boehringer Ingelheim International GmbH and Alnylam Pharmaceuticals, Inc. Between Dicerna and its collaborative partners, they currently have more than 20 active discovery, preclinical or clinical programs focused on rare, cardiometabolic, viral, chronic liver and complement-mediated diseases, as well as neurodegenerative diseases and pain. Dicerna's mission is to interfere - to silence genes, to fight disease, to restore health.
Dicerna Pharmaceuticals Inc executives and other stock owners filed with the SEC include: